Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122296 | PMC |
| http://dx.doi.org/10.4103/0019-5154.193700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-label dermatologic uses of IL-23 inhibitors.
J Dermatolog Treat
December 2024
Department of Dermatology, University of Illinois College of Medicine, Chicago, IL, USA.
Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.
Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.
Assessing the Relationship Between Vitiligo and Major Depressive Disorder Severity: Cross-Sectional Study.
JMIR Dermatol
July 2024
Department of Psychiatry, Al-Amal Complex for Mental Health, Madinah, Saudi Arabia.
Background: Vitiligo, a common dermatological disorder in Saudi Arabia, is associated with significant psychological impacts. This study explores the relationship between vitiligo and the severity of major depressive disorder (MDD), highlighting the broader implications on mental health among affected individuals.
Objective: We aim to assess the prevalence and predictors of depression among adult patients with vitiligo, and to examine the relationship between MDD severity and vitiligo.
Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report.
SAGE Open Med Case Rep
February 2024
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Article Synopsis
- - Vitiligo is an autoimmune skin disorder that causes loss of pigment, and new treatments like Janus Kinase inhibitors are showing promise for managing it.
- - A case study involving a 61-year-old man with resistant vitiligo showed significant improvement after using oral Abrocitinib, a JAK inhibitor, for 2 months after prior treatments plateaued.
- - More research, including ongoing clinical trials, is essential to evaluate the long-term effectiveness and safety of these oral Janus Kinase inhibitors for treating vitiligo.
Circadian clock gene expression and polymorphism in non-segmental vitiligo.
Mol Biol Rep
January 2024
Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Shebin AlKom, Egypt.
Background: Vitiligo is an acquired and progressive mucocutaneous disease with the damage of functioning epidermal melanocytes. Metabolic syndrome is associated with inflammatory skin diseases incorporating vitiligo. The circadian dysfunction triggers the pathogenesis of metabolic diseases, so our study aimed to determine the relationship between aryl hydrocarbon receptor nuclear translocator-like gene, a ligand-activated transcription factor and sensor of environmental chemicals, expression and polymorphism with non-segmental vitiligo, as well as its effect on lipid profile.
View Article and Find Full Text PDFAcrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report.
Front Oncol
October 2023
Oncology Division, Ziv Medical Centre, Safed, Israel.
Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we report a case of a woman who developed diffuse depigmented macules on the face, arms and legs, three months after initiating alpelisib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!